Figures & data
Figure 1 Physical characteristic of drug-loaded magnetic nanoparticles. (A) The nanoparticles under the transmission electron microscope. (B) Hydrodynamic particle size distribution of DNR/BrTet-loaded MNPs by Malvern Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK). (C) Magnetizaion as a function of field drug-loaded iron oxide nanoparticles by a vibration sample magnetometer. (D) Release of DNR and BrTet from MNPs under in-vitro conditions.
Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle.
![Figure 1 Physical characteristic of drug-loaded magnetic nanoparticles. (A) The nanoparticles under the transmission electron microscope. (B) Hydrodynamic particle size distribution of DNR/BrTet-loaded MNPs by Malvern Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK). (C) Magnetizaion as a function of field drug-loaded iron oxide nanoparticles by a vibration sample magnetometer. (D) Release of DNR and BrTet from MNPs under in-vitro conditions.Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle.](/cms/asset/ddfe3231-ffcf-431a-97a7-eb05299f8b7d/dijn_a_24309_f0001_c.jpg)
Table 1 Drug loading of DNR and BrTet in MNPs (n = 3, mean ± standard deviation)
Table 2 Effect of MNPs and BrTet on K562/A02 cells for 48 hours (n = 3, mean ± standard deviation)
Figure 2 Cytotoxicity effects on K562/A02 cells for 48 hours. (A) DNR with or without MNPs. (B) Co-administration of DNR and BrTet with or without MNPs.
Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle; W, weight.
![Figure 2 Cytotoxicity effects on K562/A02 cells for 48 hours. (A) DNR with or without MNPs. (B) Co-administration of DNR and BrTet with or without MNPs.Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle; W, weight.](/cms/asset/3153f3f1-9328-43bf-97cb-4f1925069965/dijn_a_24309_f0002_b.jpg)
Figure 3 Subcellular distribution of DNR in K562/A02 cells treated with DNR alone, DNR-MNPs, DNR/BrTet, and DNR/BrTet-MNPs under fluorescence microscope.
Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle.
![Figure 3 Subcellular distribution of DNR in K562/A02 cells treated with DNR alone, DNR-MNPs, DNR/BrTet, and DNR/BrTet-MNPs under fluorescence microscope.Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle.](/cms/asset/71ab3097-4a58-4c2f-94cd-4db57e316f9b/dijn_a_24309_f0003_c.jpg)
Figure 4 Function of P-gp in K562/A02 cells. (A) Intracellular fluorescence intensity (FI) associated with R123 in treated cells: (a) control; (b) DNR; (c) BrTet; (d) DNR/ BrTet; (e) DNR-MNPs; (f) BrTet-MNPs; (g) DNR/BrTet-MNPs; (h) MNPs. (B) Relative R123 accumulation in K562/A02 cells. Data are presented as means ± standard deviation (n = 3) and analyzed using one-way analysis of variance.
Note: *P < 0.05, when compared with control group.
Abbreviations: BrTet, 5-bromotetrandrin; DNR, daunorubicin; FITC-H, heavy chain fluorescein isothiocyanate; MNP, magnetic nanoparticle; P-gp, P-glycoprotein; R123, rhodamine 123; RT-PCR, reverse transcriptase polymerase chain reaction.
![Figure 4 Function of P-gp in K562/A02 cells. (A) Intracellular fluorescence intensity (FI) associated with R123 in treated cells: (a) control; (b) DNR; (c) BrTet; (d) DNR/ BrTet; (e) DNR-MNPs; (f) BrTet-MNPs; (g) DNR/BrTet-MNPs; (h) MNPs. (B) Relative R123 accumulation in K562/A02 cells. Data are presented as means ± standard deviation (n = 3) and analyzed using one-way analysis of variance.Note: *P < 0.05, when compared with control group.Abbreviations: BrTet, 5-bromotetrandrin; DNR, daunorubicin; FITC-H, heavy chain fluorescein isothiocyanate; MNP, magnetic nanoparticle; P-gp, P-glycoprotein; R123, rhodamine 123; RT-PCR, reverse transcriptase polymerase chain reaction.](/cms/asset/f54464b2-9c97-4982-90b7-8cebd2646679/dijn_a_24309_f0004_c.jpg)
Figure 5 Transcription of mdr1 and expressions of P-gp in K562/A02 cells. (A) Transcription of mdr1 mRNA by RT-PCR; (B) expression of P-gp by western blotting assay.
Note: *P < 0.05, when compared with control group.
Abbreviations: BrTet, 5-bromotetrandrin; DNR, daunorubicin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MNP, magnetic nanoparticle; P-gp, P-glycoprotein; RT-PCR, reverse transcriptase polymerase chain reaction.
![Figure 5 Transcription of mdr1 and expressions of P-gp in K562/A02 cells. (A) Transcription of mdr1 mRNA by RT-PCR; (B) expression of P-gp by western blotting assay.Note: *P < 0.05, when compared with control group.Abbreviations: BrTet, 5-bromotetrandrin; DNR, daunorubicin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MNP, magnetic nanoparticle; P-gp, P-glycoprotein; RT-PCR, reverse transcriptase polymerase chain reaction.](/cms/asset/be4be9c7-a3e9-4633-ab0c-86ce55deb786/dijn_a_24309_f0005_c.jpg)